Fortress Biotech, Inc.
FBIOFortress Biotech, Inc. in brief
Fortress Biotech, Inc. is a listed company in the Biotechnology industry, based in California, USA. It was founded in 2006. Its market value was $74 M on 30 October 2026, which makes it the 19,888th largest listed company in the world and the 3,688th largest in the USA on this site. In the year to December 2025 it had sales of $63 M and a net profit of $7 M, about 11 cents of profit for every dollar of sales. It employs about 34 people and Lindsay A. Rosenwald is its chief executive. Its largest product and service lines by sales in 2025 were Qbrexza (40%), Emrosi (23%) and Accutane (20%). Its shares trade under the symbol FBIO (Nasdaq).
Written from the figures on this page, so it changes when they do. Dates and sources are under Sources and freshness.
About Fortress Biotech, Inc.
Fortress Biotech Inc., commonly known as Fortress Bio, is a biopharmaceutical company that acquires, develops, and commercializes innovative pharmaceutical and biotechnology products. Led by CEO Lindsay A. Rosenwald, M.D., Fortress and most of its subsidiary companies are headquartered in Bay Harbor Islands, Florida.
From Wikipedia: read the full article · text available under CC BY-SA 4.0
Fortress Biotech, Inc. timeline
- 2006
- 🏁· approximateFounded
- 2008
- •· approximateFirst filing with the US SECThe company's first electronic filing in SEC EDGAR.
- 2015
- ✎Renamed Fortress Biotech, Inc.Formerly Coronado Biosciences Inc.
- 2023
- 💰Record revenue of $85 millionFY2023, the highest of the 8 years on record.
- 2025
- 💰Record net income of $37 millionFY2025, the highest profit of the 4 years on record.
Events of Fortress Biotech, Inc. from Wikidata, SEC EDGAR and the company's financial years. Dates marked approximate come from statements without a cited source. Spotted a mistake? Use the correction form below.
Market cap history
World rank over time
Rank in USA: #3,277 (Jan 2020) · #2,898 (Jan 2021) · #3,677 (Jan 2022) · #4,653 (Dec 2022) · #4,470 (Jul 2023) · #4,110 (Jan 2024) · #1,926 (Mar 2026) · #3,437 (Aug 2026) · #3,715 (Oct 2026) · #3,692 (Oct 2026)
Key ratios
- P/E ratio (TTM)
- 0.7×
- Price / sales (TTM)
- 1.1×
- Price / book
- 1.5×
- Free cash flow yield
- -109.0%
- Net margin (TTM)
- 163.3%
- Operating margin
- -111.0%
- Return on equity
- 224.2%
- Liabilities / assets
- 66.5%
- Net debt
- $-25M
- Revenue growth
- +9.7%
- R&D / revenue
- 18.8%
- Revenue per employee
- $1.9 M
- Profit per employee
- $201 K
Financial history
| Fiscal year ending | Revenue | Growth | Operating income | Net income | Net margin |
|---|---|---|---|---|---|
| Dec 2025 | $63M | +9.7% | $-70M | $7M | 10.8% |
| Dec 2024 | $58M | -31.7% | $-110M | $-46M | -79.8% |
| Dec 2023 | $85M | +11.6% | $-142M | $-61M | -71.8% |
| Dec 2022 | $76M | +10.1% | $-204M | $-87M | -114.3% |
| Dec 2021 | $69M | +50.9% | $-189M | $-65M | -94.1% |
| Dec 2020 | $46M | +24.5% | $-94M | $-47M | -102.0% |
| Dec 2019 | $37M | +36.3% | $-111M | $-40M | -109.1% |
| Dec 2018 | $27M | — | $-120M | $-84M | -313.1% |
Cash flow, debt and per share
| Fiscal year ending | Operating cash flow | Capital spending | Free cash flow | EPS (diluted) | Dividend / share |
|---|---|---|---|---|---|
| Dec 2025 | $-66M | — | — | $-0.07 | — |
| Dec 2024 | $-80M | $0M | $-80M | $-2.69 | — |
| Dec 2023 | $-128M | $0M | $-128M | $-8.47 | — |
| Dec 2022 | $-179M | $3M | $-182M | $-15.97 | — |
| Dec 2021 | $-117M | $5M | $-121M | $-0.79 | — |
| Dec 2020 | $-84M | $2M | $-86M | $-0.65 | — |
| Dec 2019 | $-95M | $2M | $-97M | $-0.73 | — |
| Dec 2018 | $-99M | $7M | $-106M | $-1.94 | — |
Quarterly results
Latest quarter to Sep 2026: revenue $19M (+8.7% on a year earlier), net income $-6M. Lighter bars: fourth quarters worked out from the annual report. Trailing 12 months to Jun 2026.
SEC filings
- Oct 1, 20268-KCurrent reportOther events
- Aug 13, 202610-QQuarterly report · period to Jun 2026
- Aug 13, 20268-KCurrent reportResults of operations
- Jun 23, 20268-KCurrent reportShareholder vote
- May 14, 202610-QQuarterly report · period to Mar 2026
- May 14, 20268-KCurrent reportResults of operations
- Apr 28, 2026DEF 14AProxy statement
- Mar 31, 202610-KAnnual report · period to Dec 2025
- Mar 31, 20268-KCurrent reportResults of operations
- Mar 30, 20268-KCurrent reportOther events
- Feb 23, 20268-KCurrent reportMaterial agreement · New financial obligation · Other events
- Jan 13, 20268-KCurrent reportOther events
Official filings of Fortress Biotech, Inc. with the US Securities and Exchange Commission.
Annual results
- Revenue
- $63 M
- Operating income
- $-70 M
- Net income
- $7 M
For year ending December-2025 · source: SEC filing
Balance sheet
- Total assets
- $186 M
- Total liabilities
- $123 M
- Total equity
- $50 M
As of December-2025
Top 60 institutional investors in Fortress Biotech, Inc.#
| # | Institution | Shares held | Change (shares) | % held | Value | Filed |
|---|---|---|---|---|---|---|
| 1 | Millennium Management LLC | 2,165,401 | New | 5.89% | $5 M | Nov 16, 2026 |
| 2 | Vanguard Capital Management LLC | 1,037,203 | 0 (0.00%) | 2.82% | $2 M | Nov 13, 2026 |
| 3 | Opaleye Management Inc. | 720,000 | -170,000 (-19.10%) | 1.96% | $2 M | Nov 16, 2026 |
| 4 | Mackenzie Financial Corp | 528,913 | -26,763 (-4.82%) | 1.44% | $1 M | Nov 2, 2026 |
| 5 | Acadian Asset Management LLC | 459,016 | +351,713 (+327.78%) | 1.25% | $1 M | Nov 9, 2026 |
| 6 | Shikiar Asset Management Inc | 305,469 | 0 (0.00%) | 0.83% | $1 M | Oct 20, 2026 |
| 7 | Geode Capital Management, LLC | 285,178 | -15,343 (-5.11%) | 0.78% | $1 M | Nov 6, 2026 |
| 8 | Bridgeway Capital Management, LLC | 227,368 | +50,000 (+28.19%) | 0.62% | $0 M | Nov 16, 2026 |
| 9 | Panagora Asset Management Inc | 226,593 | +160,568 (+243.19%) | 0.62% | $0 M | Nov 12, 2026 |
| 10 | BlackRock, Inc. | 220,714 | -4,068 (-1.81%) | 0.60% | $0 M | Nov 13, 2026 |
| 11 | Marshall Wace, LLP | 215,825 | New | 0.59% | $0 M | Nov 13, 2026 |
| 12 | Citadel Advisors LLC | 169,109 | +92,044 (+119.44%) | 0.46% | $0 M | Nov 16, 2026 |
| 13 | Two Sigma Investments, LP | 148,115 | -65,671 (-30.72%) | 0.40% | $0 M | Nov 16, 2026 |
| 14 | Vanguard Fiduciary Trust Co | 146,608 | -19,763 (-11.88%) | 0.40% | $0 M | Nov 13, 2026 |
| 15 | Susquehanna International Group, LLP | 129,924 | +82,922 (+176.42%) | 0.35% | $0 M | Nov 16, 2026 |
| 16 | Jane Street Group, LLC | 119,491 | +94,077 (+370.18%) | 0.32% | $0 M | Nov 12, 2026 |
| 17 | HB Wealth Management, LLC | 117,925 | +1,250 (+1.07%) | 0.32% | $0 M | Oct 23, 2026 |
| 18 | State Street Corp | 116,801 | +15,200 (+14.96%) | 0.32% | $0 M | Nov 12, 2026 |
| 19 | Kestra Advisory Services, LLC | 102,235 | -14,000 (-12.04%) | 0.28% | $0 M | Nov 2, 2026 |
| 20 | XTX Topco Ltd | 82,493 | New | 0.22% | $0 M | Nov 16, 2026 |
| 21 | Northern Trust Corp | 63,632 | 0 (0.00%) | 0.17% | $0 M | Nov 16, 2026 |
| 22 | Prelude Capital Management, LLC | 53,366 | +11,859 (+28.57%) | 0.15% | $0 M | Nov 16, 2026 |
| 23 | 180 Wealth Advisors, LLC | 48,200 | -13,400 (-21.75%) | 0.13% | $0 M | Nov 3, 2026 |
| 24 | Integrated Wealth Concepts LLC | 45,200 | 0 (0.00%) | 0.12% | $0 M | Nov 17, 2026 |
| 25 | UBS Group AG | 42,407 | -9,939 (-18.99%) | 0.12% | $0 M | Nov 10, 2026 |
Show all 60: investors 26 to 60
| # | Institution | Shares held | Change (shares) | % held | Value | Filed |
|---|---|---|---|---|---|---|
| 26 | PFG Investments, LLC | 41,501 | +5,000 (+13.70%) | 0.11% | $0 M | Nov 12, 2026 |
| 27 | LPL Financial LLC | 39,513 | New | 0.11% | $0 M | Nov 6, 2026 |
| 28 | Choreo, LLC | 36,250 | 0 (0.00%) | 0.10% | $0 M | Oct 28, 2026 |
| 29 | Employees Retirement System of Texas | 36,127 | New | 0.10% | $0 M | Nov 10, 2026 |
| 30 | Provenance Wealth Advisors, LLC | 33,500 | New | 0.09% | $0 M | Oct 30, 2026 |
| 31 | Susquehanna Portfolio Strategies, LLC | 31,126 | New | 0.08% | $0 M | Nov 16, 2026 |
| 32 | Empowered Funds, LLC | 25,000 | 0 (0.00%) | 0.07% | $0 M | Nov 13, 2026 |
| 33 | Prudential Financial Inc | 24,726 | New | 0.07% | $0 M | Nov 16, 2026 |
| 34 | Creative Planning | 21,452 | New | 0.06% | $0 M | Nov 2, 2026 |
| 35 | StoneX Group Inc. | 16,055 | New | 0.04% | $0 M | Nov 3, 2026 |
| 36 | Two Sigma Securities, LLC | 15,383 | New | 0.04% | $0 M | Nov 16, 2026 |
| 37 | Corient Private Wealth LP | 14,963 | 0 (0.00%) | 0.04% | $0 M | Nov 16, 2026 |
| 38 | Abacus Planning Group, Inc. | 14,534 | 0 (0.00%) | 0.04% | $0 M | Nov 2, 2026 |
| 39 | Tower Research Capital LLC (TRC) | 13,249 | +11,845 (+843.66%) | 0.04% | $0 M | Nov 16, 2026 |
| 40 | Universal- Beteiligungs- und Servicegesellschaft mbH | 13,163 | New | 0.04% | $0 M | Nov 10, 2026 |
| 41 | Vanguard Global Advisers, LLC | 12,578 | 0 (0.00%) | 0.03% | $0 M | Nov 13, 2026 |
| 42 | SEI Investments Co | 12,177 | New | 0.03% | $0 M | Nov 10, 2026 |
| 43 | Carlson Financial, Inc. | 12,159 | -500 (-3.95%) | 0.03% | $0 M | Nov 5, 2026 |
| 44 | NewEdge Advisors, LLC | 11,361 | -3,566 (-23.89%) | 0.03% | $0 M | Nov 13, 2026 |
| 45 | Spark Investment Management LLC | 11,100 | New | 0.03% | $0 M | Nov 13, 2026 |
| 46 | Osaic Holdings, Inc. | 10,261 | +1,200 (+13.24%) | 0.03% | $0 M | Nov 12, 2026 |
| 47 | Wells Fargo & Company/mn | 9,167 | +4,167 (+83.34%) | 0.02% | $0 M | Nov 16, 2026 |
| 48 | Simplex Trading, LLC | 8,946 | -5,562 (-38.34%) | 0.02% | $0 M | Nov 4, 2026 |
| 49 | Morgan Stanley | 5,040 | +1,540 (+44.00%) | 0.01% | $0 M | Nov 13, 2026 |
| 50 | Rockefeller Capital Management L.P. | 4,812 | 0 (0.00%) | 0.01% | $0 M | Nov 13, 2026 |
| 51 | Arax Advisory Partners | 4,086 | 0 (0.00%) | 0.01% | $0 M | Nov 12, 2026 |
| 52 | SBI Securities Co., Ltd. | 3,650 | 0 (0.00%) | 0.01% | $0 M | Oct 22, 2026 |
| 53 | Highbridge Capital Management LLC | 3,340 | New | 0.01% | $0 M | Nov 16, 2026 |
| 54 | Royal Bank Of Canada | 1,886 | +1,161 (+160.14%) | 0.01% | $0 M | Nov 16, 2026 |
| 55 | FMR LLC | 910 | New | 0.00% | $0 M | Nov 10, 2026 |
| 56 | Jpmorgan Chase & Co | 339 | 0 (0.00%) | 0.00% | $0 M | Nov 12, 2026 |
| 57 | Larson Financial Group LLC | 37 | 0 (0.00%) | 0.00% | $0 M | Nov 5, 2026 |
| 58 | Northwestern Mutual Wealth Management Co | 33 | 0 (0.00%) | 0.00% | $0 M | Nov 13, 2026 |
| 59 | Barclays PLC | 8 | -986 (-99.20%) | 0.00% | $0 M | Nov 6, 2026 |
| 60 | Caitong International Asset Management Co., Ltd | 7 | -37 (-84.09%) | 0.00% | $0 M | Oct 29, 2026 |
Mutual funds holding Fortress Biotech, Inc.#
| Fund | Shares | Value | Of the company | Of the fund | Change in shares | Report |
|---|---|---|---|---|---|---|
| 🇺🇸 Vanguard Total Stock Market Index FundThe Vanguard Group, Inc. | 697,802 | $2 M | — | <0.01% | no change | Jun 30, 2026 |
| 🇺🇸 Vanguard Extended Market Index FundThe Vanguard Group, Inc. | 279,891 | $1 M | — | <0.01% | +12% | Jun 30, 2026 |
| 🇺🇸 Fidelity Extended Market Index FundFidelity Management & Research Company LLC | 131,019 | $0 M | — | <0.01% | +0.5% | May 31, 2026 |
| 🇺🇸 iShares Micro-Cap ETFBlackRock Fund Advisors | 88,143 | $0 M | — | 0.02% | +43% | Jun 30, 2026 |
| 🇺🇸 Fidelity Total Market Index FundFidelity Management & Research Company LLC | 49,359 | $0 M | — | <0.01% | no change | May 31, 2026 |
| 🇺🇸 Fidelity Series Total Market Index FundFidelity Management & Research Company LLC | 35,874 | $0 M | — | <0.01% | +11% | May 31, 2026 |
| 🇺🇸 EA Bridgeway Omni Small-Cap Value ETFEmpowered Funds, LLC d/b/a EA Advisers | 25,000 | $0 M | — | 0% | new | Jun 30, 2026 |
| 🇺🇸 Fidelity Nasdaq Composite Index FundFidelity Management & Research Company LLC | 20,365 | $0 M | — | <0.01% | +243% | May 31, 2026 |
| 🇺🇸 Vanguard Institutional Total Stock Market Index FundThe Vanguard Group, Inc. | 18,051 | $0 M | — | <0.01% | new | Jun 30, 2026 |
| 🇺🇸 Vanguard Balanced Index FundThe Vanguard Group, Inc. | 10,255 | $0 M | — | <0.01% | −47% | Jun 30, 2026 |
| 🇺🇸 Nomura Healthcare FundDelaware Management Company | 6,666 | $0 M | — | <0.01% | no change | Jun 30, 2026 |
| 🇺🇸 1290 VT Micro Cap PortfolioEquitable Investment Management Group, LLC | 5,933 | $0 M | — | <0.01% | +23% | Jun 30, 2026 |
| 🇺🇸 Total Stock Market Index TrustJohn Hancock Variable Trust Advisers LLC | 728 | $0 M | — | <0.01% | no change | Jun 30, 2026 |
| 🇺🇸 Blackstone Alternative Multi-Strategy FundBlackstone Alternative Investment Advisors LLC | 20 | $0 M | — | <0.01% | no change | Jun 30, 2026 |
Source: Fund portfolio reports to the SEC (Form N-PORT), CVM, Finansinspektionen and Indian fund houses · as of Jun 30, 2026. The 14 largest positions, each from the fund's newest report; report dates differ between funds. A fund family's funds are listed one by one, so one manager can appear many times.
Insider trading at Fortress Biotech, Inc.#
Shares bought and sold by directors, officers and 10% owners, from their SEC Form 4 filings.
| Traded | Insider | Trade | Shares | Price | Value | Owned after | Filing |
|---|---|---|---|---|---|---|---|
| filed | David JinChief Financial Officer | Grant or award | +1,190 | $1.819 | $2 K | 1.65 M | Form 4 |
| filed | David JinChief Financial Officer | Grant or award | +400,000 | — | — | 1.65 M | Form 4 |
| filed | David JinChief Financial Officer | Grant or award | +2,967 | $2.180 | $6 K | 1.25 M | Form 4 |
| filed | Michael S. WeissExecutive Vice Chairman, Director | Grant or award | +475,424 | — | — | 2.28 M | Form 4 |
| filed | Lindsay A. RosenwaldPRESIDENT, CEO & CHAIRMAN, Director, 10% owner | Grant or award | +475,424 | — | — | 4.59 M | Form 4 |
| filed | Kevin LorenzDirector | Grant or award | +27,322 | — | — | 101,009 | Form 4 |
| filed | Malcolm HoenleinDirector | Grant or award | +27,322 | — | — | 115,747 | Form 4 |
| filed | J. Jay LobellDirector | Grant or award | +27,322 | — | — | 192,397 | Form 4 |
Source: SEC Forms 4 and 5. Awards, option exercises and shares withheld for tax are listed but not counted in the totals
Markets and events: Fortress Biotech, Inc.#
Short interest, dividends, buybacks, splits, index changes and other events from FINRA, the SEC and the exchanges.
Stock splits: 1-for-14.99 reverse split
| Dividend, quarter | Per share | |
|---|---|---|
| Q3 2024 | $0.000 |
| Buybacks, quarter | Fiscal | Spent |
|---|---|---|
| Q3 2021 | Q3 2021 | $0M |
| Q2 2021 | Q2 2021 | $0M |
| Q1 2021 | Q1 2021 | $0M |
| Q4 2020 | Q4 2020 | $0M |
| Q3 2020 | Q3 2021 | $0M |
| Q2 2020 | Q2 2021 | $0M |
| Q1 2020 | Q1 2021 | $0.1M |
| Q3 2018 | Q3 2018 | $0M |
| Q3 2017 | Q3 2018 | $0M |
Fails to deliver
- : 35 shares at $2.00
- : 46 shares at $1.96
- : 85 shares at $1.93
- : 88 shares at $1.93
- : 85 shares at $1.94
Source: FINRA, SEC EDGAR (8-K, S-1/F-1, 424B4, XBRL, fails-to-deliver), Nasdaq Trader, Wikipedia index change tables
Fortress Biotech, Inc. scorecard#
Passes 14 of the 26 checks that could be worked out: strongest in valuation (4 of 5), weakest in financial health (2 of 6). Fiscal year 2025; market cap of Oct 30, 2026.
Valuation4 of 5
- ✓P/E below its peers' median0.7×P/E 0.7× against Biotechnology's median of 17.5×.
- ✓Price to book below its peers' median1.5×Price to book 1.5× against Biotechnology's median of 2.9×.
- ✓Price to sales below its peers' median1.1×Price to sales 1.1× against Biotechnology's median of 8.7×.
- ✗Free cash flow yield above 5%-109.0%Free cash flow is -109.0% of the market value.
- ✓Earnings yield above the 10-year Treasury yield151.5%Earnings yield 151.5% against the 10-year Treasury's 5.15% on 2026-11-13.
- –The price assumes slower growth than the last three years'Free cash flow of the last three years is missing or below zero on average.
Growth3 of 6
- ✓Revenue grew in the newest year9.7%Revenue up 9.7% in fiscal 2025.
- ✗Revenue up more than 5% a year over three years-5.8%-5.8% a year over the three years to fiscal 2025.
- ✗Faster growth over three years than its peers' median-5.8%-5.8% a year against Biotechnology's median of 12.9% (181 companies).
- ✗Earnings per share grew in the newest year-0.07 vs -2.69Diluted EPS -0.07 in fiscal 2025 against -2.69 the year before (report's currency).
- ✓Net income higher than five years earlier$7 M$7 M in fiscal 2025 against -$47 M in 2020.
- ✓Revenue rose in at least four of the last five years4 of 5Revenue rose in 4 of the five years to fiscal 2025.
Profitability3 of 5
- ✓Profitable in the newest year$7 MNet income $7 M in fiscal 2025.
- ✗Profitable in each of the last five years1 of 5Profitable in 1 of the five years to fiscal 2025.
- ✗Operating margin above its peers' median-111.0%-111.0% against Biotechnology's median of -60.5% (243 companies).
- ✓Return on equity above 15%18.8%18.8% in fiscal 2025.
- –Return on invested capital above 10%No return on invested capital on file.
- ✓Operating margin wider than three years earlier-111.0%-111.0% in fiscal 2025 against -268.8% in 2022.
Financial health2 of 6
- ✓Short-term assets cover short-term liabilities2.5×Current ratio 2.49 at the end of fiscal 2025.
- ✗Debt below equity1.1×Debt to equity 1.09 at the end of fiscal 2025.
- ✓Net debt below three years of EBITDANet cashMore cash than debt: net cash of $25 M at the end of fiscal 2025.
- ✗Operating income covers interest five times-7.0×Operating income -7.0 times interest in fiscal 2025.
- ✗Cash from operations positive in each of the last three years0 of 3Positive in 0 of the three years to fiscal 2025.
- ✗Altman Z-score outside the distress zone-5.61Z-score -5.61 (distress zone) for fiscal 2025.
Shareholder returns2 of 4
- ✓Pays a dividendYesPaid dividends in fiscal 2025.
- –Dividend per share raised five years in a rowSix years of dividends per share are not on file.
- ✓Dividends under 75% of net income9.7%Dividends were 9.7% of net income in fiscal 2025.
- ✗Share count up no more than 2% in a year34.2%Diluted shares up 34.2% in fiscal 2025.
- ✗Dividends and buybacks above 3% of the market value0.9%Dividends and buybacks were 0.9% of the market value.
- –Free cash flow covers dividends and buybacksCash from operations or capital spending is not on file.
Worked out from the statements as filed (sec), the medians of Biotechnology, the 10-year Treasury yield of Nov 13, 2026 and the market cap. A check that cannot be worked out counts neither way. A reading aid, not advice. How the checks work
Financial analysis, 2025#
Worked out from Fortress Biotech, Inc.'s statements, beside the median of Biotechnology.
| Ratio | Trend | 2025 | Median of peers |
|---|---|---|---|
| Operating margin | -111.0% | -60.5% | |
| Net margin | 10.8% | -68.9% | |
| Return on equity | 18.8% | -61.0% | |
| Revenue growth, 3 years a year | -5.8% | 12.9% | |
| Revenue growth | 9.7% | 15.8% | |
| Debt to equity | 1.09× | 0.26× |
5of 9on the Piotroski tests of financial strength
- Only -965% of net income arrived as cash from operations.
- The share count rose 34.2% in the year.
- Operating income covers the interest bill only -7.0 times.
- Receivables grew 191% while revenue grew 10%: customers are paying later, or sales were booked ahead of cash.
Fortress Biotech, Inc.: financial statements#
Income statement, balance sheet and cash-flow statement as reported, newest period first.
Amounts in USD millions; per-share figures in USD; share counts in millions. Hover a figure for its filing and XBRL tag. Growth compares with the year before; shares are of revenue (income and cash flow) or of total assets (balance sheet).
| Period | Trend | FY 2025to Dec 31, 2025 | FY 2024to Dec 31, 2024 | FY 2023to Dec 31, 2023 | FY 2022to Dec 31, 2022 | FY 2021to Dec 31, 2021 | FY 2020to Dec 31, 2020 | FY 2019to Dec 31, 2019 | FY 2018to Dec 31, 2018 | FY 2017to Dec 31, 2017 | FY 2016to Dec 31, 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income statement | |||||||||||
| Revenue | 63+9.7%100% | 58−31.8%100% | 85+11.6%100% | 76+10.1%100% | 69+50.9%100% | 46+24.5%100% | 37+36.3%100% | 27−85.7%100% | 188+1038%100% | 16—100% | |
| Cost of revenue | 21+0.2%33.1% | 21−8.8%36.2% | 23r27−25.6%27.1% | 31−4.1%40.6% | 32+120%46.6% | 15+38.6%32.0% | 11+72.0%28.8% | 6.1+67.4%22.8% | 3.7+363%2.0% | 0.8r−0.8—4.8% | |
| Research and development | 12−79.0%18.8% | 57−46.6%98.2% | 106−21.4%126% | 135+4.7%178% | 129+101%187% | 64−21.2%141% | 81−6.9%222% | 87r83+80.8%325% | 48r52+37.5%25.8% | 35r−35—213% | |
| Selling, general and administrative | 96+9.9%152% | 88−3.6%152% | 91r94−20.0%108% | 114+30.9%150% | 87+42.0%126% | 61+10.0%134% | 56+4.2%152% | 53—199% | — | — | |
| Selling and marketing | — | — | — | — | — | 17+1.5%38.1% | 17+47.1%46.7% | 12+11.8%43.3% | 10+80.3%5.5% | 5.8—35.0% | |
| General and administrative | — | — | — | — | — | 44+13.8%96.0% | 38−7.8%105% | 42r53−18.0%155% | 51r40+80.3%27.1% | 28r−28—171% | |
| Operating expenses | — | — | — | — | — | — | — | 147+37.2%546% | 107r289+30.2%57.1% | 82—499% | |
| Total costs and expenses | 133−20.6%211% | 168−25.9%291% | 227−18.8%268% | 279+8.5%369% | 257+84.0%374% | 140−5.1%307% | 147+0.4%403% | 147—546% | — | — | |
| Operating income | −70—−111% | −110—−191% | −142—−168% | −204—−269% | −189—−274% | −94—−207% | −111—−303% | −120—−446% | −90r−101—−47.9% | −66—−399% | |
| Interest and finance income | 2.5−7.4%3.9% | 2.7−10.7%4.7% | 3.0+115%3.6% | 1.4+115%1.8% | 0.6−57.2%0.9% | 1.5−40.7%3.3% | 2.6+132%7.0% | 1.1+34.8%4.1% | 0.8+175%0.4% | 0.3—1.8% | |
| Interest expense and finance costs | 10−25.3%16.0% | 14−11.7%23.5% | 15+22.7%18.1% | 12−18.5%16.5% | 15−0.1%22.3% | 15+29.3%33.6% | 12—32.3% | — | 5.9+58.8%3.1% | 3.7—22.4% | |
| Net interest income | — | — | — | — | — | — | 0.0+14.6%0.0% | 0.0+34.5%0.0% | 0.0—0.0% | — | |
| Other non-operating income (expense) | 37—58.0% | −10—−17.6% | −11—−13.4% | −9.9−141%−13.1% | 24—35.2% | −8.6−194%−18.8% | 9.2—25.0% | −11—−40.2% | −7.7r2.9—−4.1% | −5.6—−33.9% | |
| Income before tax | −34—−53.0% | −121—−209% | −154—−182% | −213—−282% | −164—−239% | −103—−226% | −102—−278% | −131—−487% | −98r−98—−52.0% | −71—−433% | |
| Income tax | −0.6−299%−1.0% | 0.3−40.1%0.5% | 0.5+16.0%0.6% | 0.4−5.1%0.6% | 0.5−5.4%0.7% | 0.5r0.1—1.1% | 0—0.0% | 0−100%0.0% | 1.5—0.8% | 0—0.0% | |
| Income from discontinued operations | — | — | — | — | — | — | 0—0.0% | −11—−41.4% | −2.3—−1.2% | — | |
| Net income including minority interests | −33—−52.0% | −121—−210% | −154—−182% | −214—−282% | −165—−240% | −103—−226% | −102—−278% | −142—−528% | −100—−53.2% | −71—−433% | |
| Minority interests' share of net income | −40—−62.8% | −75—−130% | −94—−111% | −127—−168% | −100—−146% | −56—−124% | −62—−168% | −58—−215% | −33—−17.6% | −16—−98.3% | |
| Net income attributable to shareholders | 6.8—10.8% | −46—−79.8% | −61—−71.7% | −87—−114% | −65—−94.1% | −47—−102% | −40—−109% | −84—−313% | −67—−35.7% | −55—−334% | |
| Earnings per share, basic | -0.07—— | -2.69—— | -8.47—— | -15.97r-0.97—— | -0.79—— | -0.65—— | -0.73—— | -1.94—— | -1.61—— | -1.38—— | |
| Earnings per share, diluted | -0.07—— | -2.69—— | -8.47—— | -15.97r-0.97—— | -0.79—— | -0.65—— | -0.73—— | -1.94—— | -1.61—— | -1.38—— | |
| Shares, weighted average (basic) | 28+34.2%— | 21+156%— | 8.1+36.9%— | 5.9r89−92.7%— | 82—— | — | — | — | — | — | |
| Shares, weighted average (diluted) | 28+34.2%— | 21+156%— | 8.1+36.9%— | 5.9r89−92.7%— | 82+13.5%— | 72+31.6%— | 55+25.9%— | 43+4.3%— | 42+4.2%— | 40—— | |
| Balance sheet | |||||||||||
| Cash and cash equivalents | 79+38.6%42.8% | 57−29.2%39.7% | 81−54.6%48.3% | 178−41.7%60.6% | 306+31.0%77.1% | 233+70.5%70.0% | 137+109%60.4% | 66−31.0%46.5% | 95r114−9.7%38.6% | 105r88—61.6% | |
| Short-term investments | — | — | — | — | — | — | 0−100%0.0% | 18−51.1%12.5% | 36—14.6% | 0—0.0% | |
| Receivables | 30+191%16.1% | 10−32.8%7.1% | 15−46.0%9.1% | 28+22.0%9.6% | 23−3.4%5.8% | 24r19+76.7%7.2% | 14+146%6.0% | 5.5−29.1%3.9% | 7.8+324%3.2% | 1.8—1.1% | |
| Inventory | 9.6−33.3%5.2% | 14+41.4%10.0% | 10−27.9%6.1% | 14+43.6%4.8% | 9.9+602%2.5% | 1.4+63.8%0.4% | 0.9+26.4%0.4% | 0.7+296%0.5% | 0.2−15.8%0.1% | 0.2—0.1% | |
| Other current assets | 4.9−31.2%2.6% | 7.1−32.3%4.9% | 11+8.7%6.3% | 9.7+36.7%3.3% | 7.1+5.1%1.8% | 6.7+62.7%2.0% | 4.1−38.6%1.8% | 6.7+17.5%4.8% | 5.7r13−36.7%2.3% | 9.1—5.3% | |
| Current assets | 124+37.0%66.7% | 90−22.8%62.7% | 117−49.2%69.9% | 230−33.5%78.3% | 346+30.2%87.4% | 266r262+70.3%79.8% | 156+40.5%69.0% | 111−39.3%78.9% | 183+67.1%74.5% | 110—64.2% | |
| Property, plant and equipment | 2.5−22.7%1.4% | 3.3−49.9%2.3% | 6.5−50.0%3.9% | 13−13.6%4.4% | 15+26.4%3.8% | 12−4.1%3.6% | 12+3.4%5.5% | 12+68.9%8.5% | 7.1r9.5−3.5%2.9% | 7.4—4.3% | |
| Right-of-use (leased) assets | 12−11.2%6.6% | 14−18.4%9.6% | 17−15.0%10.1% | 20+5.2%6.8% | 19−7.2%4.8% | 20−4.6%6.1% | 21—9.5% | 0—0.0% | — | — | |
| Goodwill | — | — | — | — | — | — | — | — | 190.0%7.6% | 19—10.9% | |
| Other intangible assets | 28−13.4%14.9% | 32+57.1%22.1% | 20−25.4%12.1% | 27+117%9.2% | 13−14.2%3.2% | 15+98.3%4.4% | 7.4+421%3.3% | 1.4+60.5%1.0% | 0.9r15−94.9%0.4% | 17—10.2% | |
| Investments in associates | 15—8.1% | — | — | — | — | — | — | — | 0.30.0%0.1% | 0.3—0.2% | |
| Long-term investments | — | — | — | — | 0−100%0.0% | 18+57.6%5.3% | 11—4.9% | 0−100%0.0% | 1.4−1.7%0.6% | 1.4—0.8% | |
| Total assets | 186+28.7%100% | 144−13.9%100% | 168−43.1%100% | 294−25.8%100% | 397+18.9%100% | 333r329+47.3%100% | 226+60.6%100% | 141−42.7%100% | 246+44.1%100% | 171—100% | |
| Accounts payable | 14−55.0%7.7% | 32−9.1%21.9% | 35−39.2%20.8% | 57+20.7%19.5% | 47+316%12.0% | 11r41−67.8%3.4% | 35+4.1%15.7% | 34+24.3%24.2% | 27r36+12.8%11.1% | 24r24—14.2% | |
| Current liabilities | 50−30.3%26.8% | 71−15.9%49.5% | 85−33.5%50.7% | 128+26.4%43.4% | 101+95.2%25.5% | 52r48+13.5%15.5% | 46−18.0%20.1% | 56−22.2%39.4% | 71r67+26.3%29.0% | 57—33.1% | |
| Lease liabilities (non-current) | 13−14.1%6.8% | 15−19.3%10.2% | 18−15.3%10.9% | 22+2.8%7.3% | 21−8.3%5.3% | 23−3.5%6.9% | 24—10.5% | 0—0.0% | — | — | |
| Total liabilities | 123−15.4%66.5% | 146−12.1%101% | 166−32.1%99.1% | 244+43.2%83.0% | 171+25.1%43.0% | 136r132−11.4%40.9% | 154+26.9%68.0% | 121−3.3%86.0% | 125+42.9%51.0% | 88—51.4% | |
| Retained earnings | −734—−396% | −741—−514% | −695—−415% | −634—−216% | −547—−138% | −483—−145% | −436—−193% | −396—−281% | −312—−127% | −245—−144% | |
| Shareholders' equity | 50+119%26.9% | 23+0.9%15.8% | 23−46.0%13.5% | 42−61.6%14.2% | 109+8.3%27.4% | 100+283%30.1% | 26+1315%11.6% | 1.9−96.5%1.3% | 53+36.6%21.4% | 38—22.5% | |
| Minority interests | 12—6.6% | −24—−16.9% | −21−352%−12.5% | 8.3−92.9%2.8% | 117+21.3%29.6% | 97+109%29.0% | 46+159%20.5% | 18−73.7%12.7% | 68+52.7%27.6% | 44—26.0% | |
| Total equity | 62—33.5% | −1.6−204%−1.1% | 1.6−96.8%0.9% | 50−77.9%17.0% | 226+14.7%57.0% | 197+172%59.1% | 73+267%32.0% | 20−83.6%14.0% | 121+45.2%49.0% | 83—48.6% | |
| Total liabilities and equity | 186+28.7%100% | 144−13.9%100% | 168−43.1%100% | 294−25.8%100% | 397+18.9%100% | 333r329+47.3%100% | 226+60.6%100% | 141−42.7%100% | 246+44.1%100% | 171—100% | |
| Shares outstanding | 31+12.4%— | 28+84.9%— | 15+105%— | 7.4r110−92.7%— | 101+6.9%— | 95+28.2%— | 74+28.0%— | 58+13.4%— | 51+4.2%— | 49—— | |
| Cash-flow statement | |||||||||||
| Depreciation and amortization | — | — | — | — | — | — | — | — | 1.2+23.4%0.6% | 0.9—5.7% | |
| Share-based compensation | 29−11.9%45.4% | 33+91.5%56.6% | 17−25.9%20.1% | 23+18.0%30.3% | 19+44.9%28.3% | 13+2.0%29.5% | 13−12.2%36.0% | 15+12.0%55.8% | 13r14+10.5%7.1% | 12—73.6% | |
| Cash from operating activities | −66—−104% | −80—−139% | −128—−152% | −179—−237% | −117—−169% | −84—−184% | −95—−259% | −99—−368% | −81r−85—−43.3% | −46r−46—−278% | |
| Capital expenditure | — | 0—0.0% | −0.1—−0.1% | −2.7—−3.6% | −4.6—−6.6% | −1.9—−4.2% | −2.3—−6.4% | −7.1—−26.3% | −0.6r−2.1—−0.3% | −6.4—−38.7% | |
| Intangible assets bought | 0—0.0% | −15—−26.0% | −5.0—−5.9% | 0—0.0% | −0.4—−0.6% | −1.2—−2.6% | −2.4—−6.6% | −1.2—−4.5% | 0—0.0% | −0.4—−2.1% | |
| Acquisitions, net of cash acquired | — | — | — | — | — | — | — | — | −4.6—−2.5% | −4.6—−28.1% | |
| Cash from investing activities | 10—16.0% | −15—−26.0% | −2.1—−2.5% | −23−157%−30.3% | 41—58.9% | −7.2−136%−15.7% | 20+6.8%54.9% | 19—70.0% | −40r−42—−21.4% | −6.1—−36.8% | |
| Debt issued | — | — | — | 47—62.2% | 0—0.0% | — | — | — | — | — | |
| Debt repaid | — | 0—0.0% | −50—−59.6% | 0—0.0% | −10—−15.2% | — | — | — | — | — | |
| Shares issued | 1.0−73.0%1.6% | 3.7+82.9%6.5% | 2.0−66.3%2.4% | 6.1−33.4%8.0% | 9.1−80.2%13.2% | 46r48+122%101% | 21+107%56.5% | 10—37.2% | — | 0—0.0% | |
| Shares bought back | — | — | — | — | — | −0.1—−0.2% | 0—0.0% | — | — | — | |
| Dividends paid | −0.7—−1.0% | −0.7—−1.2% | −0.7—−0.9% | −0.7—−1.0% | −0.7—−1.1% | −0.2—−0.5% | 0—0.0% | — | — | — | |
| Cash from financing activities | 77+9.6%122% | 71+116%122% | 33−56.5%38.7% | 75−49.4%99.4% | 149−13.6%217% | 172+17.5%378% | 147+190%401% | 51−66.3%188% | 150r154+250%80.2% | 43r42—260% | |
| Change in cash | 22—34.4% | −25—−42.6% | −98—−115% | −127−274%−168% | 73−10.5%106% | 82+13.5%179% | 72—196% | −29−202%−109% | 29r27—15.4% | −9.0r−9.9—−54.4% | |
| Report | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K/A | 10-K | 10-K | 10-K | |
r Changed after it was first reported (a restatement, a reclassification or a later report's rounding); hover for the first value and filing, or show every figure as first reported: what investors could read at the time, without look-ahead. Restatements across companies
Amounts in USD millions; per-share figures in USD; share counts in millions. Hover a figure for its filing and XBRL tag. Growth compares with the same quarter a year before; shares are of revenue (income and cash flow) or of total assets (balance sheet).
| Period | Trend | Last 12 months4 quarters to Sep 30, 2026 | Q3 FY2026to Sep 30, 2026 | Q2 FY2026to Jun 30, 2026 | Q1 FY2026to Mar 31, 2026 | Q4 FY2025to Dec 31, 2025 | Q3 FY2025to Sep 30, 2025 | Q2 FY2025to Jun 30, 2025 | Q1 FY2025to Mar 31, 2025 | Q4 FY2024to Dec 31, 2024 | Q3 FY2024to Sep 30, 2024 | Q2 FY2024to Jun 30, 2024 | Q1 FY2024to Mar 31, 2024 | Q4 FY2023to Dec 31, 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||||||||
| Revenue | 70+12.3%100% | 19+8.7%100% | 19+14.0%100% | 16+22.1%100% | 16*+6.3%100% | 18+20.5%100% | 16+10.2%100% | 13+0.8%100% | 15*−24.2%100% | 15—100% | 15—100% | 13—100% | 20*—100% | |
| Cost of revenue | 24+17.5%33.8% | 5.9+2.2%30.7% | 6.1+24.4%32.8% | 6.2+29.8%38.8% | 5.4*+16.2%33.8% | 5.8+28.7%32.6% | 4.9−13.8%30.1% | 4.8−20.2%36.5% | 4.7r2.2*+108%31.0% | 4.5r5.3—30.6% | 5.7r6.5—38.4% | 6.0r6.8—46.1% | 2.2r6.0*—11.3% | |
| Research and development | — | 1.7+707%8.8% | 0.8−90.1%4.3% | 0.5−86.3%3.4% | — | 0.2−97.8%1.2% | 8.1−35.9%49.5% | 3.9−84.1%30.0% | 9.7*−31.2%64.1% | 9.4—64.6% | 13—85.1% | 25—191% | 14*—70.6% | |
| Selling, general and administrative | 69−36.3%98.9% | 18+2.3%93.0% | 21−46.3%111% | 16−38.1%99.1% | 15*−45.2%91.6% | 17−20.8%98.8% | 39+86.1%236% | 26+43.0%195% | 27*+38.0%178% | 22—150% | 21—140% | 18—138% | 19r23*—97.6% | |
| Total costs and expenses | 100−34.3%142% | 26+7.8%138% | 29−45.7%153% | 24−32.9%148% | 21*−46.4%130% | 24−33.4%139% | 53+23.9%322% | 35−28.5%270% | 39*−1.5%258% | 37—251% | 43—287% | 50—381% | 40*—198% | |
| Operating income | −30—−42.5% | −7.2—−37.5% | −10—−53.5% | −7.7—−48.3% | −4.8*—−29.8% | −6.8—−38.6% | −36—−222% | −22—−170% | −24*—−158% | −22—−151% | −28—−187% | −37—−281% | −20*—−98.3% | |
| Interest and finance income | 4.1+72.0%5.8% | 1.3+76.0%6.8% | 1.6+154%8.4% | 0.6+16.3%3.6% | 0.6*+21.1%4.0% | 0.7+25.0%4.2% | 0.6−15.3%3.8% | 0.5−41.2%3.7% | 0.5*−25.6%3.5% | 0.6—4.0% | 0.7—4.9% | 0.8—6.4% | 0.7*—3.5% | |
| Interest expense and finance costs | 9.4−12.0%13.4% | 2.5−8.9%13.0% | 1.5−41.4%7.9% | 3.4+20.1%21.0% | 2.0*−21.3%12.7% | 2.7−55.8%15.6% | 2.5+18.7%15.3% | 2.8+7.8%21.3% | 2.6*+25.9%17.2% | 6.2—42.4% | 2.1—14.2% | 2.6—20.0% | 2.1*—10.3% | |
| Other non-operating income (expense) | 158+340%226% | −1.1−107%−5.8% | 11−56.0%58.4% | 150—935% | −1.4*—−8.9% | 16—88.8% | 25—151% | −2.4—−18.1% | −2.1*—−14.2% | −4.5—−31.0% | −1.0—−7.0% | −2.5—−18.9% | −9.0*—−45.1% | |
| Income before tax | 129—184% | −8.3−194%−43.4% | 0.9—4.9% | 142—887% | −6.2*—−38.6% | 8.9—50.2% | −12—−71.0% | −25—−188% | −26*—−172% | −27—−182% | — | — | −29*—−143% | |
| Income tax | 4.6+1165%6.5% | −0.1−315%−0.3% | 0.3—1.7% | 5.1—32.0% | −0.8*−343%−5.1% | 0.0−62.3%0.1% | 0—0.0% | 0—0.0% | 0.3*−11.3%2.2% | 0.1—0.5% | 0—0.0% | 0—0.0% | 0.4*—1.9% | |
| Net income including minority interests | 124—177% | −8.3−194%−43.1% | 0.6—3.2% | 137—855% | −5.4*—−33.6% | 8.8—50.1% | −12—−71.0% | −25—−188% | −26*—−174% | −27—−182% | −29—−194% | −39—−299% | −29*—−145% | |
| Minority interests' share of net income | 24—34.3% | −2.4−181%−12.6% | 1.1—5.7% | 27—167% | −1.5*—−9.1% | 3.0—16.9% | −27—−165% | −14—−107% | −20*—−129% | −14—−94.5% | −18—−120% | −24—−181% | −20*—−98.8% | |
| Net income attributable to shareholders | 100+2411%143% | −5.8−200%−30.5% | −0.5−103%−2.5% | 110—688% | −3.9*—−24.5% | 5.9—33.2% | 15—94.4% | −11—−80.6% | −6.8*—−44.7% | −13—−88.0% | −11—−73.5% | −15—−118% | −9.3*—−46.5% | |
| Earnings per share, basic | — | -0.23−277%— | -0.08−116%— | 3.44—— | — | 0.13—— | 0.50—— | -0.48—— | — | -0.76—— | -0.73—— | -1.04r-1.03—— | — | |
| Earnings per share, diluted | — | -0.23−309%— | -0.08−118%— | 2.82—— | — | 0.11—— | 0.45—— | -0.48—— | — | -0.76—— | -0.73—— | -1.04—— | — | |
| Shares, weighted average (basic) | 34+23.9%— | 34+23.9%— | 32+18.3%— | 32+19.2%— | — | 27+38.3%— | 27+46.7%— | 26+54.2%— | — | 20—— | 18—— | 17—— | — | |
| Shares, weighted average (diluted) | 34+2.0%— | 34+2.0%— | 32+6.6%— | 38+45.2%— | — | 33+68.0%— | 30+62.8%— | 26+54.2%— | — | 20—— | 18—— | 17—— | — | |
| Dividends per share | — | — | — | — | — | — | — | — | — | 0.00—— | — | — | — | |
| Balance sheet | ||||||||||||||
| Cash and cash equivalents | 152—54.3% | 152+76.5%54.3% | 197+164%62.1% | 256+180%71.7% | 79+38.6%42.8% | 86+46.5%47.5% | 74−2.4%46.5% | 91+9.0%51.3% | 57−29.2%39.7% | 59—46.3% | 76—52.3% | 84—50.9% | 81—48.3% | |
| Receivables | 47—16.9% | 47+164%16.9% | 36+132%11.4% | 25+38.7%7.0% | 30+191%16.1% | 18+68.5%9.9% | 16+49.5%9.8% | 18+83.9%10.1% | 10−32.8%7.1% | 11—8.4% | 10—7.2% | 9.8—6.0% | 15—9.1% | |
| Inventory | 7.8—2.8% | 7.8−34.2%2.8% | 8.2−36.5%2.6% | 9.3−25.6%2.6% | 9.6−33.3%5.2% | 12+0.3%6.5% | 13+32.7%8.0% | 12+18.1%7.0% | 14+41.4%10.0% | 12—9.3% | 9.7—6.6% | 11—6.4% | 10—6.1% | |
| Other current assets | 3.0—1.1% | 3.0+26.6%1.1% | 4.0−42.2%1.3% | 4.8+2.2%1.4% | 4.9−31.2%2.6% | 2.3−9.3%1.3% | 7.0+49.6%4.4% | 4.7−60.8%2.7% | 7.1−32.3%4.9% | 2.6—2.0% | 4.6—3.2% | 12—7.3% | 11—6.3% | |
| Current assets | 210—75.1% | 210+77.5%75.1% | 246+122%77.5% | 295+133%82.8% | 124+37.0%66.7% | 119+37.4%65.3% | 110+6.7%69.0% | 127+8.9%71.3% | 90−22.8%62.7% | 86—67.9% | 103—71.0% | 117—70.8% | 117—69.9% | |
| Property, plant and equipment | 2.3—0.8% | 2.3−11.1%0.8% | 2.4−10.8%0.8% | 2.4−13.2%0.7% | 2.5−22.7%1.4% | 2.6−23.3%1.4% | 2.7−23.7%1.7% | 2.8−54.4%1.6% | 3.3−49.9%2.3% | 3.4—2.7% | 3.5—2.4% | 6.1—3.7% | 6.5—3.9% | |
| Right-of-use (leased) assets | 11—3.9% | 11−10.5%3.9% | 11−11.4%3.6% | 12−11.1%3.3% | 12−11.2%6.6% | 12−12.9%6.8% | 13−12.4%8.0% | 13−19.2%7.5% | 14−18.4%9.6% | 14—11.1% | 15—10.0% | 16—10.0% | 17—10.1% | |
| Other intangible assets | 25—8.8% | 25−14.4%8.8% | 26−14.2%8.1% | 26−14.0%7.4% | 28−13.4%14.9% | 29+60.7%15.8% | 30+59.4%18.6% | 31+58.2%17.3% | 32+57.1%22.1% | 18—14.0% | 19—12.8% | 19—11.8% | 20—12.1% | |
| Investments in associates | 12—4.2% | 12−21.8%4.2% | — | 1.0—0.3% | 15—8.1% | 15—8.3% | — | — | — | — | — | — | — | |
| Total assets | 280—100% | 280+54.5%100% | 317+98.1%100% | 357+100%100% | 186+28.7%100% | 181+42.7%100% | 160+9.8%100% | 178+8.2%100% | 144−13.9%100% | 127—100% | 146—100% | 165—100% | 168—100% | |
| Accounts payable | 13—4.6% | 13−31.2%4.6% | 12−41.3%3.7% | 14−49.2%4.0% | 14−55.0%7.7% | 19−44.8%10.3% | 20−46.8%12.6% | 28−33.5%15.6% | 32−9.1%21.9% | 34—26.8% | 38—26.1% | 42—25.4% | 35—20.8% | |
| Current liabilities | 72—25.6% | 72+32.7%25.6% | 62+7.8%19.6% | 103+40.3%29.0% | 50−30.3%26.8% | 54−23.1%29.8% | 58−23.9%36.0% | 74−16.0%41.4% | 71−15.9%49.5% | 70—55.3% | 76—51.9% | 88—53.3% | 85—50.7% | |
| Lease liabilities (non-current) | 11—3.9% | 11−14.9%3.9% | 11−13.8%3.6% | 12−13.0%3.4% | 13−14.1%6.8% | 13−16.5%7.0% | 13−16.5%8.3% | 14−21.6%7.8% | 15−19.3%10.2% | 15—12.0% | 16—10.9% | 18—10.7% | 18—10.9% | |
| Total liabilities | 103—36.8% | 103−11.2%36.8% | 111−9.7%34.9% | 155+6.1%43.3% | 123−15.4%66.5% | 116−16.9%64.1% | 123−23.6%76.6% | 146−13.6%81.8% | 146−12.1%101% | 140—110% | 160—110% | 169—102% | 166—99.1% | |
| Retained earnings | −630—−225% | −630—−225% | −624—−197% | −624—−175% | −734—−396% | −730—−402% | −736—−460% | −751—−422% | −741—−514% | −734—−578% | −721—−495% | −710—−431% | −695—−415% | |
| Shareholders' equity | 160—57.1% | 160+186%57.1% | 164+274%51.8% | 162+629%45.5% | 50+119%26.9% | 56+164%30.8% | 44+146%27.5% | 22−3.4%12.5% | 23+0.9%15.8% | 21—16.6% | 18—12.3% | 23—14.0% | 23—13.5% | |
| Minority interests | 17—6.1% | 17+82.6%6.1% | 42—13.2% | 40+292%11.3% | 12—6.6% | 9.3—5.1% | −6.5—−4.1% | 10—5.7% | −24—−16.9% | −34—−26.7% | −32—−22.3% | −27—−16.4% | −21—−12.5% | |
| Total equity | 177—63.2% | 177+172%63.2% | 206+451%65.1% | 202+523%56.7% | 62—33.5% | 65—35.9% | 37—23.4% | 32—18.2% | −1.6−204%−1.1% | −13—−10.0% | −15—−10.0% | −3.9—−2.4% | 1.6—0.9% | |
| Total liabilities and equity | 280—100% | 280+54.5%100% | 317+98.1%100% | 357+100%100% | 186+28.7%100% | 181+42.7%100% | 160+9.8%100% | 178+8.2%100% | 144−13.9%100% | 127—100% | 146—100% | 165—100% | 168—100% | |
| Shares outstanding | 33—— | 33+8.0%— | 33+12.0%— | 33+12.3%— | 31+12.4%— | 31+12.4%— | 30+31.7%— | 30+52.5%— | 28+84.9%— | 28—— | 23—— | 19—— | 15—— | |
| Cash-flow statement | ||||||||||||||
| Share-based compensation | 9.2−78.2%13.2% | 2.1−32.8%11.2% | 2.9−82.9%15.4% | 1.8−72.1%10.9% | 2.5*−84.8%15.3% | 3.2−51.4%18.1% | 17+236%102% | 6.3+29.5%47.9% | 16*+337%107% | 6.6—44.9% | 5.0—33.6% | 4.9—37.3% | 3.7*—18.6% | |
| Cash from operating activities | 126—180% | −6.2*—−32.3% | −59*—−317% | 204—1271% | −13*—−78.0% | −6.1*—−34.7% | −28*—−168% | −20—−149% | −13*—−85.4% | −20*—−137% | −22*—−147% | −25—−195% | −35*—−175% | |
| Capital expenditure | — | −0.0*—−0.0% | — | — | — | — | — | — | 0*—0.0% | 0*—0.0% | — | — | −0.0*—−0.1% | |
| Intangible assets bought | — | — | — | — | — | — | — | — | −15*—−99.2% | — | — | — | 0*—0.0% | |
| Cash from investing activities | −0.1—−0.1% | −0.0*−100%−0.0% | −0.1*−101%−0.4% | 0−100%0.0% | 0*—0.0% | 2.9*—16.3% | 6.1*—37.1% | 1.2—8.9% | −15*—−99.2% | 0*—0.0% | 0*—0.0% | 0—0.0% | −0.1*—−0.3% | |
| Debt repaid | — | — | — | — | — | — | — | — | 0*—0.0% | 0*—0.0% | — | — | 0*—0.0% | |
| Shares issued | — | — | — | 0−100%0.0% | 0*−100%0.0% | 0*−100%0.0% | −0.0*−100%−0.0% | 1.0+12.9%7.7% | 0.3*—2.2% | 0.6*—3.9% | 1.9*—13.0% | 0.9—6.9% | −0.0*—−0.1% | |
| Dividends paid | — | — | — | 0—0.0% | −0.2*—−1.0% | −0.2*—−0.9% | −0.2*—−1.0% | −0.2—−1.3% | −0.2*—−1.1% | −0.2*—−1.2% | −0.2*—−1.2% | −0.2—−1.4% | −0.2*—−0.9% | |
| Cash from financing activities | −60−161%−85.4% | −38*−353%−199% | 0.1*−98.0%0.5% | −27−153%−171% | 5.7*−77.9%35.5% | 15*+456%85.5% | 4.5*−68.3%27.5% | 52+87.2%397% | 26*−40.8%171% | 2.7*—18.5% | 14*—95.8% | 28—214% | 44*—219% | |
| Change in cash | 66+149%94.2% | −44*−475%−232% | −59*—−317% | 176+423%1100% | −6.8*—−42.5% | 12*—67.1% | −17*—−103% | 34+1265%257% | −2.1*−124%−13.9% | −17*—−119% | −7.6*—−50.8% | 2.5—19.0% | 8.6*—43.2% | |
| Report | Worked out | 10-Q | 10-Q | 10-Q | 10-Q | 10-Q | 10-Q | 10-Q | 10-K | 10-Q | 10-Q | 10-Q | 10-K | |
* Worked out from reported figures: a quarter the company states only within a year-to-date figure (cash flows are reported that way), or the fourth quarter as the fiscal year minus the first nine months.
r Changed after it was first reported (a restatement, a reclassification or a later report's rounding); hover for the first value and filing, or show every figure as first reported: what investors could read at the time, without look-ahead. Restatements across companies
Build a DCF model from these statements: revenue, margins, tax, depreciation, capital spending, working capital, debt, cash and shares filled in from the annual reports, every assumption yours.
Source: SEC EDGAR filings (XBRL) · as of Sep 30, 2026. A fiscal year is listed under the calendar year it mostly falls in; quarters are numbered within the company's fiscal year. Balance-sheet figures are those at the end of each period. Payments in the cash-flow statement are negative
What Fortress Biotech, Inc. sells: revenue by product line, fiscal 2025#
As the company reports it, in US dollars, with each line's share of total revenue and the change on fiscal 2024. Lines can overlap (a total and its parts), so they are not added up.
Products and services
- Qbrexza$25 M40%-0.4%
- Emrosi$15 M23%—
- Accutane$13 M20%-34%
- Foam franchise products (Amzeeq & Zilxi)$6 M9.3%-12%
- Other / legacy product revenue$3 M4.3%-31%
Business segments
- Journey$62 M98%+10%
- Avenue$1 M2.2%—
Source: SEC annual report (XBRL data) · as of Dec 31, 2025
Executive pay at Fortress Biotech, Inc.#
From the pay-versus-performance table of the company's proxy statement. “Actually paid” marks share awards to their current value.
| Fiscal year | CEO total pay | Actually paid | Other executives, average | $100 invested |
|---|---|---|---|---|
| 2025Year | $2.9 M | $3.6 M | $1.6 M | — |
| 2024Year | $1.4 M | $808 K | $1.9 M | — |
| 2023Year | $1.1 M | −$1.9 M | $1.2 M | — |
Source: SEC proxy statement (Form DEF 14A) · as of Dec 31, 2025
Events at Fortress Biotech, Inc.#
What the company reported to the SEC within four business days (Form 8-K), newest first.
No warning signs in the last three years: no bankruptcy, delisting notice, withdrawn financial statements, auditor change, cybersecurity incident, debt called early or impairment was reported.
Acquisition or sale completed 1 · Directors and officers 1 · Material agreement 4 · New debt 2 · Unregistered share sale 2 · Shareholder vote 2 · Results announced 8
| Filed | What happened | Filing |
|---|---|---|
| Results announced | 8-K | |
| Shareholder vote | 8-K | |
| Results announced | 8-K | |
| Results announced | 8-K | |
| Material agreementNew debt | 8-K | |
| Material agreementNew debtUnregistered share sale | 8-K | |
| Results announced | 8-K | |
| Results announced | 8-K | |
| Shareholder vote | 8-K | |
| Acquisition or sale completed | 8-K | |
| Results announced | 8-K | |
| Directors and officers | 8-K | |
| Results announced | 8-K | |
| Material agreement | 8-K | |
| Results announced | 8-K | |
| Material agreementUnregistered share sale | 8-K |
Source: SEC EDGAR, Form 8-K item numbers · as of Aug 13, 2026
Acquisitions and funding#
5 private funding rounds before listing
Private share sales · funding history
| Month | Raised | Raise | Size | Investors | Sold | Filing |
|---|---|---|---|---|---|---|
| Mar 2017 | $3 M | Private placement after listing | $2 to $10 million | 2 | debt, options | SEC |
| May 2011 | $26 M | No. 5 | $10 to $50 million | 344 | equity, options | SEC |
| Jan 2011 | $14 M | No. 4 | $10 to $50 million | 1 | equity | SEC |
| May 2010 | $4 M | No. 3 | $2 to $10 million | 41 | equity, options | SEC |
| Apr 2010 | $7 M | No. 2 | $2 to $10 million | 25 | equity, options | SEC |
| Jul 2009 | $1 M | No. 1 | Under $2 million | 16 | debt, options | SEC |
Source: Annual reports and Form D notices filed with the SEC; Wikidata. Acquisitions are the businesses the company reports as acquired in its newest annual report, with the price paid. Funding rounds do not name their investors; the investors listed are those Wikidata records.
Lobbying by Fortress Biotech, Inc.#
$20 K spent on lobbying the US Congress and federal agencies in 2025, most often on health issues.
- Health Issues1 report
Lobbying firms hired in 2025
THE VOGEL GROUP $20 K
| Year | Spending | Own lobbyists | Reports |
|---|---|---|---|
| 2026 (so far) | $20 K | — | 2 |
| 2025 | $20 K | — | 1 |
Source: Lobbying Disclosure Act reports (Form LD-2). Filed as “Fortress Biotech Inc.”. Reports round to the nearest $10,000, and one of less than $5,000 counts as zero
How Fortress Biotech, Inc. compares in Biotechnology
- Market cap$74 M · higher than 32% of 726
- Revenue$63 M · higher than 62% of 647
- Revenue growth9.7% · higher than 53% of 438
- P/E ratio0.7× · lower than 99% of 100
- Price / sales1.1× · lower than 92% of 339
- Price / book1.5× · lower than 68% of 534
- FCF yield-109.0% · higher than 9% of 449
Peer comparison · Biotechnology
| Company | Market cap | P/E | Net margin | Rev. growth |
|---|---|---|---|---|
| Fortress Biotech, Inc.🇺🇸 | $74 M | 0.7× | — | +9.7% |
| Novo Nordisk A/S🇩🇰 | $203.2 B | 13.1× | 33.1% | +10.8% |
| Vertex Pharmaceuticals Incorporated🇺🇸 | $134.3 B | 33.8× | 30.7% | +8.9% |
| Moderna, Inc.🇺🇸 | $90.1 B | — | -110.5% | -39.9% |
| Regeneron Pharmaceuticals, Inc.🇺🇸 | $84.1 B | 17.5× | 28.5% | +1.0% |
| Argenx SE🇳🇱 | $52.8 B | 40.9× | 31.1% | +89.9% |
| CSL Limited🇦🇺 | $51.6 B | — | -16.4% | — |
| Samsung Biologics Co., Ltd.🇰🇷 | $51.5 B | 40.5× | 39.2% | — |
| UCB SA🇧🇪 | $48.6 B | 26.3× | 20.1% | +31.1% |
P/E and margins use trailing 12-month results where available; growth is the latest fiscal year.
Questions, comparisons and similar companies#
Questions people ask
Compare head to head
Similar companies by size and industry
- Regenxbio Inc.$513 M
- Pharmicell Co., Ltd.$514 M
- Pulike Biological Engineering, Inc.$524 M
- Contineum Therapeutics, Inc.$534 M
- Entera Bio Ltd.$543 M
- Arvinas, Inc.$544 M
Sources and freshness
- Market cap:
- Oct 30, 2026
- Annual results:
- For year ending December-2025
- Balance sheet:
- As of December-2025
- Employees:
- 2016
- Profile updated:
- Nov 20, 2026
Figures from Market data, SEC filing, Wikidata, value.today research, Wikipedia, GLEIF register; financial statements from SEC filings.
How each figure is collected: data sources and methodology. Market caps in US dollars unless you switch the currency.
Work at Fortress Biotech, Inc.? Verify and update this profile — free
Show Fortress Biotech, Inc.'s ranking or a chart on your website Get the badge
The badge updates itself as the ranking changes.